Leptin Reduction as a Required Component for Weight Loss

Author:

Zhao Shangang123,Li Na14,Xiong Wei5,Li Guannan3,He Sijia3,Zhang Zhuzhen6,Zhu Qingzhang1,Jiang Nisi3,Ikejiofor Christian3,Zhu Yi7,Wang May-Yun1,Han Xianlin3,Zhang Ningyang5,Solis-Herrera Carolina2,Kusminski Christine1,An Zhiqiang5,Elmquist Joel K.8,Scherer Philipp E.1ORCID

Affiliation:

1. 1Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX

2. 2Division of Endocrinology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX

3. 3Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX

4. 4Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China

5. 5Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX

6. 6College of Life Sciences, Wuhan University, Wuhan, China

7. 7Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX

8. 8Division of Hypothalamic Research, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX

Abstract

Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance. Article Highlights

Funder

National Institutes of Health

American Heart Association

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3